Eltrombopag Viatris is a medicine that is used for the treatment of: * primary immune thrombocytopenia (ITP), a disease in which the patient’s immune system destroys platelets (components in the blood that help it to clot). Patients with ITP have low platelet counts in the blood (thrombocytopenia) and are at risk of bleeding. Eltrombopag Viatris is used in patients from 1 year of age for whom treatment with medicines such as corticosteroids or immunoglobulins has not worked. In children and adolescents, the medicine is used when they have had the disease for at least 6 months; * thrombocytopenia in adults with chronic (long\-term) hepatitis C, a liver disease caused by the hepatitis C virus. Eltrombopag Viatris is used when the thrombocytopenia is too severe to allow interferon\-based therapy (a type of treatment for hepatitis C). Eltrombopag Viatris contains the active substance eltrombopag and is a ‘generic medicine’. This means that Eltrombopag Viatris contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Eltrombopag Viatris is Revolade. For more information on generic medicines, see the question\-and\-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf).
Therapeutic Indication
Eltrombopag Viatris is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Eltrombopag Viatris is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4\.2 and 5\.1\). Eltrombopag Viatris is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon\-based therapy (see sections 4\.2 and 5\.1\).
Therapeutic Area (MeSH)
ATC Code
B02BX05
ATC Item
N/A
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
EMA Name
Eltrombopag Viatris
Medicine Name
Eltrombopag Viatris
Aliases
N/ANo risk management plan link.
